Polycystic kidney disease is a genetic condition in which fluid-filled sacs, called cysts, steadily multiply and enlarge inside the kidneys, crowding out healthy tissue and eventually threatening kidney function. The most common form, autosomal dominant polycystic kidney disease (ADPKD), affects roughly one in every 400 to 1,000 people worldwide, making it one of the most frequent life-threatening inherited disorders. Because cysts grow slowly over decades, many people carry the disease for years before symptoms appear, and the path from diagnosis to kidney failure varies enormously from person to person.
What Drives Cyst Formation
ADPKD arises from mutations in one of two genes. Mutations in PKD1, on chromosome 16, account for about 85 percent of cases and tend to cause more severe disease. Mutations in PKD2, on chromosome 4, make up most of the rest. Both genes encode proteins called polycystin-1 and polycystin-2, which sit on tiny hair-like structures called primary cilia that protrude from kidney cells into the fluid flowing through kidney tubules. These cilia act as antennas: they sense the flow and chemical signals in the surrounding fluid and relay that information into the cell. When the polycystin proteins are absent or defective, cilia cannot transmit those signals properly, and the affected cells begin to proliferate and secrete fluid in ways they normally would not.1PubMed Central. Cilia and polycystic kidney disease, kith and kin
Research has shown that both structural and functional defects in primary cilia lead to cystic growth and can also contribute to high blood pressure.2PubMed Central. The Roles of Primary cilia in Polycystic Kidney Disease The relationship is not simple, though. Losing the polycystin proteins causes cysts in a way that depends on cilia being present, but losing the cilia themselves causes cysts through a separate pathway entirely. In other words, two distinct biological routes can converge on the same result: a kidney full of expanding cysts.3Kidney Research and Clinical Practice. Cyst growth, polycystins, and primary cilia in autosomal dominant polycystic kidney disease
Once a cyst begins to form, a signaling molecule called cyclic AMP (cAMP) keeps it growing. In healthy kidney cells, cAMP has routine roles. In ADPKD cells, it does something unusual: it stimulates both the proliferation of cyst-lining cells and the secretion of fluid into the cyst cavity, inflating it from the inside.4PubMed. cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells A chloride channel called CFTR, the same channel implicated in cystic fibrosis, sits on the inner lining of ADPKD cysts and appears to be the main conduit through which fluid pours in.5PubMed. A role for CFTR in human autosomal dominant polycystic kidney disease Understanding these molecular gears has been critical for developing treatments.
How the Disease Is Diagnosed
Most people learn they have ADPKD through an ultrasound, often ordered after a family member is diagnosed or after an incidental finding during imaging for something else. The number of cysts needed to confirm the diagnosis depends on your age, because younger people have had less time for cysts to grow. For someone between 15 and 39 who has a parent with the disease, finding three or more cysts in one or both kidneys essentially confirms it. Between 40 and 59, the bar is at least two cysts in each kidney. After 60, the threshold rises to at least four cysts per kidney.6PubMed Central. Diagnosis and Screening of Autosomal Dominant Polycystic Kidney Disease
The flip side is harder: ruling the disease out. In a person under 30 with an affected parent, a clean ultrasound showing zero cysts still leaves roughly a 10 percent chance that ADPKD is present but too early to see. That matters a great deal when someone in the family wants to donate a kidney, because you need high confidence the donor’s kidneys are unaffected.7PubMed Central. Diagnosis and Screening of Autosomal Dominant Polycystic Kidney Disease
Genetic testing has improved considerably and is increasingly used alongside imaging. Modern sequencing can identify mutations in PKD1 and PKD2, though PKD1 is technically challenging to analyze because part of the gene is duplicated in six “pseudogenes” that look almost identical, sharing over 97 percent of their sequence.8Clinical Kidney Journal. Genetic testing in autosomal dominant polycystic kidney disease: why it matters in 2025 When the test finds a clearly harmful variant, the diagnosis is confirmed regardless of what the ultrasound shows. But among people already clinically diagnosed with ADPKD who have not previously had genetic testing, the sensitivity of genomic tests appears to be somewhere between 70 and 80 percent, meaning a negative genetic result does not rule the disease out.9Clinical Kidney Journal. The diagnostic accuracy of ultrasound and genomic tests for the diagnosis of autosomal-dominant polycystic kidney disease: a systematic mapping review In practice, many clinicians use imaging and genetics together, each filling the gaps of the other.
Tracking How Fast the Disease Progresses
One of the most frustrating aspects of ADPKD is that two people with the same gene mutation can have dramatically different outcomes. Some reach kidney failure in their forties; others retain adequate function well into their seventies. Predicting which path you are on is a major focus of current clinical practice.
The most widely used prediction tool is the Mayo Imaging Classification, which categorizes patients based on how large their kidneys are relative to their age and height. People in the higher classes (1C through 1E) are considered rapid progressors and lose kidney function faster: kidney volume grows anywhere from about 5 to 12 percent per year, and kidney filtration drops by roughly 3.5 to 4.5 milliliters per minute each year. Slower progressors in classes 1A and 1B see kidney volume growth of just 1 to 4 percent annually and a gentler decline in function.10PubMed Central. Mayo imaging classification is a good predictor of rapid progress among Korean patients with autosomal dominant polycystic kidney disease: results from the KNOW-CKD study The classification generally predicts kidney failure well, though there is still substantial individual variation within each class.11PubMed Central. Validation of the Mayo Imaging Classification System for Predicting Kidney Outcomes in ADPKD
As cysts expand, they do not just passively crowd out normal tissue. They trigger a scarring process called fibrosis. Cyst-lining cells release growth factors that activate scar-producing cells in the surrounding tissue, which lay down excess collagen and other structural proteins. This fibrosis reduces the kidney’s ability to filter blood and seems to develop in a two-phase pattern: the cysts change first, and the surrounding tissue responds second, with each phase amplifying the other.12PubMed Central. Fibrosis and progression of autosomal dominant polycystic kidney disease (ADPKD)
Blood Pressure and the Heart
High blood pressure is one of the earliest and most consequential complications. Between 10 and 20 percent of children with ADPKD already have elevated blood pressure, and the majority of adults become hypertensive before kidney function declines at all.13PubMed Central. Hypertension in autosomal dominant polycystic kidney disease The mechanism is a vicious cycle: expanding cysts compress the blood vessels inside the kidney, reducing blood flow and triggering the body’s main blood-pressure-raising system (the renin-angiotensin-aldosterone system). The resulting higher pressure then promotes further cyst growth, which compresses more vessels, and so on.
Treating blood pressure aggressively makes a measurable difference. In a landmark trial, patients with early-stage ADPKD who were treated to a lower blood pressure target saw their kidneys grow about 5.6 percent per year, compared with 6.6 percent per year in the standard-target group. The tighter control also reduced thickening of the heart muscle and lowered the amount of protein leaking into urine, both signs of cardiovascular and kidney protection.14PubMed Central. Blood pressure in early autosomal dominant polycystic kidney disease ACE inhibitors and angiotensin-receptor blockers are the standard first-line drugs. A trial comparing one of each, used alone versus combined, found no additional benefit from dual therapy in people with later-stage disease, suggesting that using one well-chosen agent at an appropriate dose is sufficient.15PubMed Central. Angiotensin Blockade in Late Autosomal Dominant Polycystic Kidney Disease
Problems Beyond the Kidneys
ADPKD is not strictly a kidney disease. Polycystin proteins are expressed throughout the body, and cysts can develop in the liver, pancreas, and other organs. Liver cysts are the most common extrarenal feature. Most people with liver cysts have no symptoms at all, but in a minority, the liver becomes massively enlarged, causing abdominal pain, fullness, and in severe cases compression of surrounding organs or even malnutrition.16PubMed Central. Polycystic liver disease: an overview of pathogenesis, clinical manifestations and management When liver cysts do become symptomatic, treatment options range from draining and shrinking individual dominant cysts to partial liver removal and, in the most extreme cases, liver transplantation.17PubMed. Polycystic liver disease: a clinical review
A more dangerous complication is the increased risk of brain aneurysms, weak spots in the walls of blood vessels inside the skull. People with ADPKD carry roughly four to five times the risk of the general population, with a prevalence of about 13 percent in screening studies.18PubMed. KDIGO 2025 Clinical Practice Guideline for ADPKD: a commentary on intracranial aneurysms and other vascular manifestations from the ERA Working Group Genes & Kidney Fortunately, most detected aneurysms are small, with a median size of about 4 millimeters, and the absolute rupture rate is low. In one large screening program, no aneurysms ruptured during follow-up among patients who were monitored, and those who needed treatment received preventive clipping or coiling before any rupture occurred.19PubMed Central. Presymptomatic Screening for Intracranial Aneurysms in Patients with Autosomal Dominant Polycystic Kidney Disease Current guidelines recommend screening with contrast-free MR angiography for people who have a family history of brain hemorrhage or aneurysm, with repeat imaging every 5 to 10 years if the initial scan is clear. Blood pressure control and not smoking are the most important modifiable factors that lower the risk of rupture.
Interestingly, blood pressure patterns at night may carry additional clues. One study found that patients with brain aneurysms had higher nighttime blood pressure spikes and more variability in their blood pressure readings than those without aneurysms, especially after age 45.20PubMed. Blood pressure and intracranial aneurysms in autosomal dominant polycystic kidney disease Whether these spikes contribute to aneurysm formation or are just a marker of more severe vascular disease is still unclear.
Tolvaptan and Disease-Modifying Treatment
For decades, managing ADPKD meant treating the complications, primarily blood pressure and pain, with no way to slow the cysts themselves. That changed with tolvaptan, a drug that blocks the vasopressin V2 receptor in the kidney. By doing so, it reduces the cAMP signaling that drives cyst growth and fluid secretion. In clinical trials, tolvaptan slowed the growth of total kidney volume and slowed the decline in kidney function compared with placebo.21PubMed Central. Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations
A systematic review and meta-analysis quantified the benefit: patients on tolvaptan retained nearly 2 additional milliliters per minute per year of kidney filtration compared with placebo and had substantially less kidney volume growth. The drug also reduced episodes of kidney pain by about a third and episodes of blood in the urine by roughly half.22Nefrología. The safety and efficacy of tolvaptan in the treatment of patients with autosomal dominant polycystic kidney disease: A systematic review and meta-analysis However, tolvaptan is not easy to take. Because it blocks water reabsorption in the kidney, patients produce large volumes of dilute urine, often more than six liters a day. Intense thirst and waking multiple times at night to urinate are nearly universal side effects: the risk of thirst was roughly three times higher than placebo, and nocturia about three times as well. There is also a rare risk of liver injury, so liver enzymes must be monitored regularly.23PubMed. Review of tolvaptan for autosomal dominant polycystic kidney disease Careful patient selection is essential, and the drug is typically reserved for people with evidence of rapid progression.
For liver cysts specifically, somatostatin analogues such as lanreotide have shown benefit. In one trial, lanreotide reduced height-adjusted total liver volume by about 2 percent over the treatment period while the control group’s livers grew by about 4 percent, a net advantage of roughly 6 percent.24Gastroenterology. Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease Another trial found lanreotide slowed kidney volume growth as well, reducing the annual rate by about 24 percent compared with controls, though it did not achieve a statistically significant difference in the rate of kidney function decline over the study period.25JAMA. Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial
Diet, Water Intake, and Ketogenic Approaches
Because vasopressin (the hormone tolvaptan blocks) is released when you are dehydrated, there has been a logical hope that simply drinking more water could achieve a milder version of the drug’s effect. In animal models, increased water intake did suppress the relevant signaling pathways and reduced cyst and kidney volume by about 28 percent.26Journal of the American Society of Nephrology. Increased Water Intake Decreases Progression of Polycystic Kidney Disease in the PCK Rat But translating that to humans has been disappointing. A three-year clinical trial that assigned patients to a prescribed high water intake found no significant difference in kidney growth compared with those who just drank as they pleased. Even though the prescribed-water group lowered their urine concentration, they did not meaningfully suppress vasopressin levels, and only about half of participants managed to hit the target urine dilution consistently.27PubMed. Prescribed Water Intake in Autosomal Dominant Polycystic Kidney Disease The takeaway is that staying well-hydrated remains generally sensible, but forcing yourself to drink large volumes of water is unlikely to slow the disease.
A more intriguing dietary avenue is ketosis. In animal models, both time-restricted feeding and ketogenic diets powerfully inhibited cyst growth, reduced fibrosis, and suppressed the signaling pathways that drive cyst expansion. Even acute fasting led to rapid cyst shrinkage in rat, mouse, and feline models. The key player appears to be beta-hydroxybutyrate (BHB), a ketone body the liver produces during fasting or carbohydrate restriction: directly supplementing BHB in animals strongly inhibited disease progression.28PubMed Central. Ketosis Ameliorates Renal Cyst Growth in Polycystic Kidney Disease The researchers propose that cyst cells have a metabolic weakness, a reliance on glucose that makes them vulnerable when the body shifts to burning fat.
Early human data has been cautiously encouraging. A systematic review of studies involving 129 ADPKD patients who tried ketogenic diets found consistent weight loss averaging about 4 kilograms, improvements in blood pressure, and beneficial effects on kidney function, though these trials were small and short-term.29PubMed Central. Therapeutic Potential of Ketogenic Interventions for Autosomal-Dominant Polycystic Kidney Disease: A Systematic Review Larger, longer trials are underway. Anyone with ADPKD interested in a ketogenic approach should work closely with their care team, since kidney disease can complicate the electrolyte shifts that come with strict carbohydrate restriction.
When Kidneys Fail
Roughly half of people with ADPKD eventually develop kidney failure requiring dialysis or transplantation, typically between their fifties and seventies, depending on which gene is affected and how fast their disease progresses. Kidney transplantation works well in ADPKD, with outcomes comparable to transplant recipients who have other causes of kidney failure.
One question specific to ADPKD is whether the enlarged native kidneys should be removed at the time of transplant. Massively enlarged kidneys can cause pain, recurring infections, or simply leave too little room in the abdomen for a transplant kidney. Studies comparing patients who had a kidney removed before or during transplant with those who did not have found no significant differences in transplant survival, kidney function, or complication rates.30Journal of Nephrology. Native nephrectomy in relation to kidney transplantation in autosomal dominant polycystic kidney disease patients; a narrative review of the literature In other words, removing the native kidney is safe when indicated but is not routinely necessary. Many surgeons prefer to perform it at the same time as transplant, particularly when the recipient is getting a living-donor kidney.31PubMed. End stage polycystic kidney disease: indications and timing of native nephrectomy relative to kidney transplantation
When nephrectomy is performed, minimally invasive surgery offers clear advantages. A large study of over 800 patients found that laparoscopic or robot-assisted approaches were associated with lower major complication rates, shorter hospital stays of about 3 days versus 6, and substantially fewer blood transfusions compared with open surgery.32PubMed Central. Perioperative Outcomes of Nephrectomy for Autosomal Dominant Polycystic Kidney Disease
The Mental Health Burden
Living with a slowly progressive, inherited kidney disease carries a psychological toll that often goes unrecognized. In one study of 38 ADPKD patients, about 60 percent had some degree of depression, yet none were receiving treatment for it, not even a referral. A larger study of 158 patients found that about 22 percent had clinically significant depression.33PubMed Central. Mental Health and Autosomal Dominant Polycystic Kidney Disease: A Narrative Review Anxiety is common too, especially the trait variety, a general tendency to feel anxious that runs deeper than worry about a single test result. The uncertainty of not knowing when, or whether, the disease will progress to kidney failure weighs on people differently depending on personality, family experience, and how much practical disruption the disease has already caused. Given these numbers, routine screening for depression and anxiety at nephrology visits would seem warranted, yet it remains the exception rather than the rule.
Prenatal and Childhood Cases
ADPKD is usually described as an adult-onset condition, and for most people it is. But it can occasionally be detected before birth. Prenatal ultrasound sometimes reveals increased echogenicity in one or both fetal kidneys, and in rare instances, visible cysts develop during the third trimester. One documented case involved a fetus with no family history of the disease whose kidneys showed progressive changes throughout pregnancy, with genetic testing after birth confirming a likely pathogenic PKD1 variant.34PubMed Central. Prenatal Diagnosis of Autosomal Dominant Polycystic Kidney Disease: Case Report These early presentations are rare precisely because the disease typically takes decades to become visible, but when they occur, they tend to signal a more aggressive course and are important for guiding family counseling.
Children with ADPKD are usually asymptomatic, but as noted earlier, 10 to 20 percent already have elevated blood pressure.35PubMed Central. Hypertension in autosomal dominant polycystic kidney disease Whether to screen children of affected parents remains a topic of debate. Knowing the diagnosis early allows monitoring and early blood pressure treatment, but it can also bring anxiety, insurance implications, and the weight of a label for a child who may not develop symptoms for decades.
Emerging Gene-Based Therapies
The treatments available today slow ADPKD but do not address its root cause. A newer line of research aims to change that by boosting the production of polycystin proteins from the remaining healthy copy of the mutated gene. ADPKD patients typically have one working copy of PKD1 or PKD2, but a small snippet within these genes’ messenger RNA acts as a landing pad for a microRNA called miR-17, which actively suppresses how much polycystin protein the cell makes. Researchers identified a six-nucleotide sequence that miR-17 binds to. When they used gene editing to disrupt just those six letters in mouse models, polycystin-1 levels increased, cyst growth decreased sharply, and kidney function improved.36Nucleic Acids Research. Disruption of a six-nucleotide miRNA motif improves PKD1 dosage and ameliorates polycystic kidney disease
Because permanent gene editing in humans remains a distant prospect for most kidney diseases, the same team developed a steric-blocking oligonucleotide, essentially a short synthetic strand that physically covers the miR-17 binding site and prevents suppression without permanently altering the DNA. This approach stabilized PKD1 messenger RNA, increased polycystin-1 levels, and reversed cyst-related changes in both mouse cells and patient-derived ADPKD cells. The same principle applies to PKD2: deleting the miR-17 binding site on PKD2 raised polycystin-2 levels and slowed cyst growth even in models where PKD1 was the mutated gene, suggesting the two polycystins can partially compensate for each other.37Nature Communications. PKD1 and PKD2 mRNA cis-inhibition drives polycystic kidney disease progression These approaches are still in preclinical stages, but they represent a fundamentally different strategy from anything currently in the clinic: instead of dampening downstream signals that make cysts grow, they try to restore the missing protein that prevents cysts from forming in the first place.
Why Animal Models Matter for Future Drugs
Much of what is known about ADPKD mechanisms, and nearly all preclinical drug testing, comes from animal models. Mouse models carrying engineered mutations in Pkd1 or Pkd2 have revealed that cyst formation requires not just the gene mutation but often an additional trigger like kidney injury, which helps explain why the disease develops slowly and unevenly across different parts of the kidney.38PubMed. Translational research in ADPKD: lessons from animal models Rat models have been especially useful for testing dietary interventions and drugs, since cellular models alone cannot capture how kidney function changes in a living organism.39PubMed Central. Experimental Models of Polycystic Kidney Disease: Applications and Therapeutic Testing
One important lesson from recent work is that genetic background matters enormously. The same Pkd1 mutation placed into different mouse strains produces vastly different disease severity, from mild cysts to rapid kidney failure. This mirrors the human experience, where two siblings with the same mutation can have very different outcomes. Researchers have started using this variability deliberately, picking mouse lines with moderate, predictable disease for standardized drug testing and using MRI to track kidney volume, mimicking the clinical approach used in human trials.40PubMed Central. The genetic background significantly impacts the severity of kidney cystic disease in the Pkd1(RC/RC) mouse model of autosomal dominant polycystic kidney disease Tolvaptan itself was validated as a positive control in this framework before being approved for human use, giving future drug candidates a clearer benchmark to beat.